Brevan Howard Capital Management LP Sells 12,464 Shares of Zoetis Inc. (NYSE:ZTS)

Brevan Howard Capital Management LP lowered its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 48.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,395 shares of the company's stock after selling 12,464 shares during the quarter. Brevan Howard Capital Management LP's holdings in Zoetis were worth $2,182,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC increased its holdings in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. grew its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Navigoe LLC bought a new position in shares of Zoetis in the fourth quarter worth $30,000. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis in the fourth quarter worth $44,000. Finally, Asset Planning Inc bought a new stake in Zoetis during the fourth quarter valued at $58,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ZTS. Stifel Nicolaus lowered their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Barclays increased their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $212.13.

Zoetis Trading Down 1.1 %

Zoetis stock traded down $1.73 during trading hours on Friday, reaching $159.96. The company had a trading volume of 4,243,109 shares, compared to its average volume of 2,491,045. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The company has a 50-day moving average price of $157.27 and a 200 day moving average price of $166.22. The firm has a market cap of $71.37 billion, a price-to-earnings ratio of 29.24, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm's revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.38 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 over the last ninety days. 0.18% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.